Portal hypertension produces an evolutive hepato-intestinal pro- and anti-inflammatory response in the rat
Related Experiment Video
Updated: Aug 17, 2026

A Rat Model of Pouchitis Following Proctocolectomy and Ileal Pouch-Anal Anastomosis Using Dextran Sulfate Sodium
Published on: May 31, 2024
Maria Dolores Palma1, Maria Angeles Aller, Elena Vara
1Surgery Chair, School of Medicine, Complutense University of Madrid, Spain.
Abstract:
An inflammatory etiopathogeny can be suggested in portal hypertensive enteropathy since infiltration of the intestinal wall by mononuclear cells has been described in this condition. This work was carried out with the intention of shedding light on this matter. Male Wistar rats were divided into 4 control groups and 4 groups with partial portal vein ligation at 1, 2, 3 and 15 months. TNF-alpha, IL-1beta and IL-10 were quantified in liver and ileum by ELISA. CO and NO were measured in splanchnic and systemic vein by spectrophotometry and Griess reaction, respectively. Expression of constitutive and inducible isoforms of NO and HO were assayed by Western blot in liver and ileum. An increased hepatic release of proinflammatory mediators (TNF-alpha, IL-1beta and NO) associated with intestinal release of anti-inflammatory mediators (IL-10, CO) occurs in an early evolutive phase (1 month) of experimental portal hypertension. On the contrary, in the long-term (15 months), the increase in the intestinal release of proinflammatory mediators (TNF-alpha, IL-1beta) is associated with an increase in the hepatic release of anti-inflammatory mediators (IL-10, CO). These results suggest that experimental prehepatic portal hypertension presents changes in the serum and tissular (liver and small bowel) concentrations of mediators which are considered as pro- and anti-inflammatory.
Insights
Portal hypertension causes inflammation in the gut. Early stages show liver inflammation and gut anti-inflammatory responses, while later stages reverse this, indicating complex mediator changes.
Area of Science:
- Gastroenterology
- Immunology
- Hepatology
Background:
- Portal hypertensive enteropathy is suspected to have an inflammatory basis.
- Mononuclear cell infiltration of the intestinal wall is observed in this condition.
Purpose of the Study:
- To investigate the inflammatory and anti-inflammatory mediator changes in experimental portal hypertension.
- To elucidate the role of cytokines and other mediators in the progression of portal hypertensive enteropathy.
Main Methods:
- Partial portal vein ligation was performed on male Wistar rats, with groups studied at 1, 2, 3, and 15 months.
- Quantification of TNF-alpha, IL-1beta, and IL-10 by ELISA.
- Measurement of CO and NO levels, and Western blot analysis for NO and HO isoforms in liver and ileum.
Main Results:
- Early portal hypertension (1 month) showed increased hepatic pro-inflammatory mediators (TNF-alpha, IL-1beta, NO) and intestinal anti-inflammatory mediators (IL-10, CO).
- Late portal hypertension (15 months) exhibited increased intestinal pro-inflammatory mediators (TNF-alpha, IL-1beta) alongside increased hepatic anti-inflammatory mediators (IL-10, CO).
Conclusions:
- Experimental prehepatic portal hypertension induces dynamic changes in pro- and anti-inflammatory mediator concentrations.
- These mediator shifts in the liver and small bowel suggest a complex inflammatory response during disease progression.
Related Concept Videos
Gastritis II: Pathophysiology
Cirrhosis II: Pathophysiology
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...

